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Purpose  
Although sodium valproate (VPA) remains the most effective antiepileptic for 
generalised and unclassified epilepsies, clinicians may be failing to discuss this 
treatment option because of guideline misinterpretation. Current guidelines 
recommend caution regarding teratogenic risks but do not advocate absolute 
avoidance.  
Methods  
We assessed VPA prescribing in young people attending a transition epilepsy clinic. 
We present six patients with idiopathic generalised epilepsy (IGE) in whom VPA had 
been initially avoided.  
Results  
Overall, the results were consistent with VPA’s superior antiepileptic efficacy and 
ability to reduce harmful seizure-related complications.  Young people denied of VPA 
showed prolonged periods of poor seizure control with medical, social and 
psychological complications.  Following contraceptive counselling and VPA 
introduction, all six patients showed improved seizure control including seizure-
freedom during follow-up of up to twenty-four months.  There was also evidence of 
reduced seizure-related morbidity and improved educational and occupational 
functioning.  Prior to referral, documentation revealed no discussion of VPA 
treatment options.  
 
Conclusion  
Failure to prescribe valproate for IGE, particularly when another first-line treatment 
has failed, may not be in a young woman’s best interests particularly when they are 
most vulnerable to sequelae from uncontrolled seizures.  Indiscriminate avoidance of 
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valproate needs to be recognised as a misinterpretation of current epilepsy guidelines 
as it may harm young people. Although the use of valproate demands careful 
consideration, there remains a strong case to always discuss this medication because 
of its efficacy and potential to reduce seizure-related harm. Patients must be allowed 
to make their own informed decisions about effective epilepsy treatments. 
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1. Introduction 
Although sodium valproate (VPA) remains the most effective antiepileptic for 
generalised and unclassified epilepsies,1-2 current guidelines3-5 appropriately 
recommend caution when prescribing the drug for young women of childbearing age.  
Lamotrigine and levetiracetam are commonly recommended alternatives largely 
because they are considered to have fewer and less severe adverse side-effects, 
including fetal teratogenicity.  These treatment guidelines are principally informed by 
observational studies including data from pregnancy registers that show higher rates 
of major somatic malformations in pregnancies exposed to VPA, for example the 
EURAP registry6 showed a rate of 5.6% with <700mg valproate and 24.2% with 
>1500mg valproate per day, 2.0% with <300mg lamotrigine per day and 4.5% with 
>300mg per day. Valproate is also associated with impaired cognitive development7 
in the absence of any fetal malformations. 
Although lamotrigine may be safer in pregnancy, it is less effective in 
controlling most seizure types that occur in the idiopathic generalised epilepsies 
(IGEs) and specifically tonic-clonic seizures; the same is also true of topiramate. 
There are inadequate comparative efficacy data for levetiracetam.  Prescribing a less 
effective treatment exposes the patient to a greater risk of continuing seizures8, 
consequent risk of injury (including rarely, death) and psychological consequences 
and social disadvantage.9,10    
Guideline developers must weigh the risk:benefit ratio of treatments when 
writing their guidance.  This is particularly challenging in this scenario as evidence 
about benefit and harm will come from many different sources. Guidance that is too 
risk-averse in terms of preventing teratogenicity might expose women to an increased 
risk of seizures, and particularly tonic-clonic seizures. In addition, the clinical 
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interpretation and implementation of guidance also requires careful consideration and 
over-cautious interpretation might have the same effect.  Finally, implementation is 
also limited by a paucity of data that identify the priorities and preferences of young 
women who are about to start treatment for epilepsy.  Such issues highlight the need 
for examining significant sequalae when operationalizing epilepsy guidelines. 
  
2. Material and Methods 
We assessed  the impact of treatment approaches for young people attending a 
transition epilepsy clinic.  We report on six young people with an IGE  seen in a 
specialist transition (teenager) epilepsy clinic in the UK accrued over 18 months.11. 
None of the patients had achieved a seizure-free period of more than six months; all 
had received a range of anti-epileptic medications, either singly or in combination, but 
never VPA.  Following discussion of the different treatment options with the young 
person and their family, all patients elected for a  trial of VPA ; six were converted to 
valproate monotherapy and one patient continued to receive valproate in combination 
with another anti-epileptic drug. Details of the six patients are shown in Table 1.  
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3. Case Series 
Five of the six patients had experienced specific adverse consequences from 
uncontrolled seizures. Prior to commencing VPA, Cases 3 and 5 had a protracted 
period lasting several years of uncontrolled seizures despite multiple trials of different 
high-dose monotherapies.  Cases 2 and 3 had tried monotherapies and combination 
therapies and reported adverse effects including renal calculi and sedation.  Two 
patients required acute medical intervention (Cases 1 and 4) for uncontrolled clusters 
of tonic-clonic seizures and two experienced mental health complications (Cases 3 
and 5) that necessitated acute psychological support and psychiatric intervention.  
All six patients demonstrated improved seizure control after commencing 
VPA, , remaining seizure and complication-free throughout the short duration of 
follow up (three to 24months).  Following seizure-cessation, social isolation and 
clinical depression reduced in Cases 3 and 5, school attendance improved in Case 3 
and continuing higher education became a reality for Case 2.  Adverse side-effects 
were experienced by Cases 2, 4 and 5 but these did not necessitate either a reduction 
in dose or withdrawal of the drug.  Although data was unavailable on whether patients 
were sexually active or using contraception, all women after referral to the transition 
service routinely received documented nurse-led counselling on contraception and 
advice about pregnancy. 
 
4. Discussion 
All six patients experienced prolonged periods of poor seizure control and 
consequently suffered physical, psychological and social complications during 
treatment regimes that had excluded VPA. Following the introduction of VPA, 
seizure control improved in all six; all had achieved seizure freedom during the four 
to 24 month follow-up.  None of the patients subsequently experienced any medical 
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complications (including injuries) whilst on valproate and a number demonstrated 
improved psychosocial functioning. This would suggest that, had VPA been 
introduced earlier in their management, they would have experienced fewer, if any, 
medical and psychological consequences associated with poor seizure control. 
Clearly, this hypothesis cannot be proven. However, the superiority of VPA compared 
to other anti-epileptic medications in enabling seizure-freedom has been demonstrated 
in randomised trials. For example, alternatives to valproate such as lamotrigine and 
topiramate for generalised epilepsies are likely to bring an increased risk of treatment 
failure and seizures (hazard ratio 1.25 and 1.89 respectively for time to treatment 
failure).1   
 
4.1 Uncontrolled seizures: Significant medical, psychological and social 
complications 
Medical complications associated with poor seizure control are well-
recognised and include accidental injuries, death (including from sudden unexpected 
death in epilepsy [SUDEP] or suicide) and mental health disorders. Anti-epileptic 
regimes that optimise seizure control are considered likely to minimise the medical 
complications and maximise quality of life.10 
Generalised tonic-clonic seizures during pregnancy can lead to fetal loss through 
severe hypoxia, direct trauma and intracranial haemorrhage.  Convulsive (tonic-
clonic) status may be associated with fetal death in 50% of cases.12 It is also possible 
that poorly controlled seizures could adversely affect psychomotor development of 
the child. Finally, poorly controlled seizures may also have financial consequences for 
the woman as well as the NHS and other healthcare institutions.  
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Three of our cases experienced significant psychological complications, two 
serious and requiring psychiatric intervention, predominantly because of poor seizure 
control. Clearly,  there may have been confounding factors, including their pre-
morbid mental health status and the adverse effects of medication, and specifically, 
topiramate. Seizures may affect relationships, self-esteem, continuing education, 
career opportunities and driving which in turn may limit social functioning, stigma 
and quality of life.10 Such factors must be carefully considered in the discussion of all 
available treatment options with young people and their families. 
 
4.2 Towards individualised Care 
Treatment options should always be tailored to a patient’s circumstances and 
priorities. There should be an open and realistic discussion about treatment 
alternatives that should include a balanced discussion of relative risks and benefits. 
Such discussions may need to occur at the time of diagnosis and particularly in girls 
of childbearing age. Whilst this might be considered a statement of the obvious, this 
approach is not always followed in clinical practice as demonstrated in all six of our 
cases where there was no documented discussion on treatment choices. It may also be 
difficult to provide a balanced discussion without prejudicial bias by the clinician.  An 
over-liberal use of valproate might result in increased fetal exposure to valproate with 
consequent malformations and cognitive delay. Conversely, overly-restricted use of 
valproate might result in unnecessary seizures and associated consequences.  
Decisions made by patients are heavily dependent upon the information 
provided by clinicians. If the clinicians’ interpretation of current evidence is that 
preventing teratogenicity is the priority, the risk of teratogenicity might be 
emphasised in any discussion and valproate might not even be offered as a treatment 
option.  
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Decisions made in clinic consultations might be helped by better evidence 
about the priorities and preferences of young people with epilepsy although there is a 
currently a dearth of such evidence.  
In conclusion, VPA is clearly an effective anti-epileptic drug but it may equally be 
associated with significant adverse side-effects including fetal teratogenicity and 
cognitive and language dysfunction in children exposed to the drug, particularly in the 
first few months of pregnancy. Valproate will always be a treatment option for the 
treatment of the generalised epilepsies and this must be openly and honestly discussed 
with the young person or teenager and where appropriate their family. This must 
include the discussion of the implications of poor seizure control and its consequences 
as well as the implications of an unplanned pregnancy on the fetus. Other factors that 
are relevant to VPA prescribing to women include the risk of weight gain and 
endocrinological side effects. Whilst there has not been a sufficiently powered study 
linking VPA to PCOS the body of evidence as it stands, strongly suggests that VPA 
has the potential to cause this disorder - which may be relevant to young women. This 
does not mean that VPA can't be used, but it does mean that weight and (if 
appropriate) the regularity of periods should be checked regularly as a bare minimum.  
The teenager’s decision will be based upon their practical priorities at the time of this 
discussion; clearly, their priorities may subsequently change depending on the young 
person’s situation, as this is a critical and dynamic time of their life. In a woman who 
is at risk of becoming pregnant, if the decision in her best interests is to prescribe 
valproate, then it should be at the lowest effective dose and in conjunction with folic 
acid and advice on contraception and pregnancy. Ultimately the woman needs to be 
given reliable, information with which to make an informed choice, and she may 
choose to continue taking VPA when planning a pregnancy, particularly if her 
epilepsy has been resistant to other treatments.  It is important that information given 
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provides patients with a balanced and un-prejudiced view about different treatment 
options that should include valproate. It must be emphasised that current epilepsy 
guidelines encourage this individual, tailored approach rather than attempting absolute 
risk-avoidance or physician-centred decision-making. Current guidelines do not state 
that valproate should be universally avoided and patients must be allowed to make 
their own informed decisions about their epilepsy treatment.  
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• Highlights 
• Sodium valproate for idiopathic generalised epilepsies has unsurpassed efficacy 
• Guidelines recommend caution offering valproate and not absolute avoidance 
• We show six young patients in whom physicians had persistently avoided 
valproate 
• Uncontrolled seizures and severe distressing sequalae followed 
• Patients must be involved and allowed to decide on their own epilepsy treatment 
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Table 1   Clinical characteristics and seizure-related outcomes before and after sodium valproate  
 
Patient no: 
sex, age 
ILAE diagnosis, 
(investigations) 
Failed treatment regimens prior to 
commencing valproate 
Type and frequency of 
seizures 
Complications before valproate monotherapy Outcomes after commencing valproate  
Uncontrolled seizures with complications 
1: F, 17 
 
 
JME diagnosed aged 12. 
tonic-clonic seizures 
(i) LEV 3g daily (maximum dose)* Continuing generalised 
tonic-clonic seizures every 
other month typically around 
menstruation 
Uncontrolled seizures.  Seizure whilst using hair 
straighteners resulting in deep lower limb burns 
requiring extensive plastic surgery 
 
Remained seizure-free throughout 14-month 
follow-up. Referred to nurse-led pre-conceptual 
counselling clinic 
2: F, 20 
 
IGE  
(EEG markedly abnormal. 
Frequent generalised onset. 
Rhythmic spike and slow 
waved activity and poly spike 
activity) 
(i) LEV 4g daily 
(ii) TOP 400mg daily  
(iii) LTG* 
Regular tonic clonic seizures 
every 6 weeks. Daily 
absence seizures 
Uncontrolled seizures.  Lamotrigine side effects: 
Admitted with renal calculus whilst on lamotrigine 
(listed as common side effect in British National 
Formulary) 
 
Remained seizure-free throughout 4-month follow-
up. Absences reduced to few times per week 
having previously been daily.  
Tiredness the only reported side effect. 
 
 
 
 
3: F, 17 
 
IGE diagnosed aged 12 
(tonic-clonic and absence 
seizures. MR Brain 
unremarkable) 
(i) LTG (maximum dose) (ii) LEV 
(iii) TOP 150mg daily and clobazam 
(iv) LEV 1.5g daily and lamotrigine 
600mg daily* 
Multiple absence seizures 
daily 
Uncontrolled seizures.  Levetiracetam side 
effects: severe sedation (“sleeping for 16 
hours/day”). Depression: “tearfulness, problems 
at school…lost interest in not just her school 
work but also her friends and leisure pursuits” - 
considered related to ongoing intrusive seizures 
Remained seizure-free throughout 20-month 
follow-up. Mood improved – may have benefited 
from both antiepileptic and antidepressant effects 
of VPA 
 
4: F, 19 
 
 
IGE  
(CT head unremarkable) 
(i) LEV 4g daily*  Tonic-clonic seizures every 2 
months, typically within an 
hour of waking, had never 
achieved seizure freedom for 
more than 4 months 
Uncontrolled seizures. Worse with Alcohol.   
Fall during seizure resulting in subluxed upper 
central incisors. Laceration to upper lip and 
mucosa requiring suturing and splinting 
 
 
Remained seizure-free throughout 43-month 
follow-up. Advised to avoid switching generic 
brands of valproate. Enrolled in university 
education. Occasional vomiting with generic 
formula, appetite increase, hair loss.  Explanation 
given on contraception and availability of different 
choices given that P450 enzyme inducers would 
not be used. Commenced on folic acid 
 
5: F, 24 
 
IGE diagnosed at 11 months  
(EEG showed generalised 
polyspike and wave 
abnormality induced by 
hyperventilation and 
associated with blinking) 
(i) ETX 
(ii) CBZ 
(iii) LTG 600mg daily and LEV 1g daily 
(iv) LTG 600mg daily, LEV 1g daily and 
clobazam 10mg daily with PRN 
clobazam 
(v) CBZ and LEV 2.5g daily* 
Treated initially with VPA as 
a young child but was 
discontinued as she grew 
older and was switched to  
ETX.  Subsequent 
worsening control of 
seizures during stressful 
periods revising for GCSE 
school examinations 
 
Uncontrolled seizures. Suffered multiple seizures 
whilst attempting to go on holiday. Required 
referral to clinical neuropsychology for stress 
counselling and CBT on her return. Substantial 
seizure psychosocial complications identified: 
“She now feels her epilepsy has affected her 
social life…[she is] unable to do very straight 
forward things such as get on a bus on her 
own…she finds it difficult at this time in her life, 
where she has stressful factors such as college 
exams and other teenage worries…” 
 
 
 
Remained seizure-free throughout 24-month 
follow-up on VPA 1g daily and LTG 150mg daily.  
Hair loss and fine tremor noted.   Orlistat 
commenced for weight gain and driving licence 
successfully applied for.  
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Uncontrolled seizures without complications 
6: M, 15 
 
JME diagnosed aged 14  
(Myoclonic, tonic-clonic and 
absence seizures, EEG 
showed generalised spike and 
wave discharges at 4hz) 
(i) LEV 2g daily for 4 months 
(ii) LTG 400mg daily added for 5 
months before referral for second 
opinion* 
Daily myoclonic seizures and 
weekly tonic-clonic seizures 
Uncontrolled seizures. “Withdrawn, refused to 
attend school and talked about self-harm 
because of daily myoclonic seizures” 
 
 
Remained seizure-free throughout 5-month follow-
up.  Increased appetite but no significant weight 
gain. School attendance improved and 
participating in all previous activities and interests 
on 1.2g VPA daily 
 
* No documented discussion or offering of valproate to patient before referral to our clinic 
CBZ=carbamazepine; CLB=clobazam; ETX=ethosuximide; LEV=levetiracetam; LTG=lamotrigine; VPA=valproate 
